Japanese Journal of Ophthalmology

, Volume 63, Issue 1, pp 1–6 | Cite as

Uveitis: contrasting the approaches in Japan and the United States

  • James T. RosenbaumEmail author
Forefront Review Organizer: Annabelle A. Okada, MD, DMSc



To compare the approaches to uveitis in Japan and the United States.


This report is based on the author’s personal experience, conversations with Japanese colleagues, and a literature search using the database of the US National Library of Medicine.


The frequencies of specific forms of uveitis vary between the two countries. Options for therapy are affected by government regulations and the impact of insurance carriers. In both countries, there is a stepwise approach to therapy beginning with topical corticosteroids and ultimately advancing to biologics. Despite the differences, the goals for therapy, disease control with minimal toxicity, are the same.


Genetic, environmental, and regulatory differences impact the approach to uveitis. Despite these factors, the goal for therapy is essentially the same.


Uveitis Japan United States Behcet’s disease Biologics 



The author is indebted to Professor Annabelle Okada for constructive comments on the contents of this manuscript and to Sandra Lewis, M.D. for assistance in preparing the bar graph.

Conflicts of interest

Consultant fees (AbbVie, Eyevensys, Gilead, Janssen, Novartis, Regeneron, Roche, UCB); Clinical trial support (Pfizer).


  1. 1.
    Rosenbaum JT. Nibbling away at the diagnosis of idiopathic uveitis. JAMA Ophthalmol. 2015;133:146–7.CrossRefGoogle Scholar
  2. 2.
    Jabs DA, Busingye J. Approach to the diagnosis of the uveitides. Am J Ophthalmol. 2013;156:228–36.CrossRefGoogle Scholar
  3. 3.
    Jakob E, Reuland MS, Mackensen F, Harsch N, Fleckenstein M, Lorenz HM, et al. Uveitis subtypes in a german interdisciplinary uveitis center–analysis of 1916 patients. J Rheumatol. 2009;36:127–36.CrossRefGoogle Scholar
  4. 4.
    Nussenblatt RB. The natural history of uveitis. Int Ophthalmol. 1990;14:303–8.CrossRefGoogle Scholar
  5. 5.
    Durrani OM, Tehrani NN, Marr JE, Moradi P, Stavrou P, Murray PI. Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol. 2004;88:1159–62.CrossRefGoogle Scholar
  6. 6.
    Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80:332–6.CrossRefGoogle Scholar
  7. 7.
    Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol. 1996;80:844–8.CrossRefGoogle Scholar
  8. 8.
    Harada E. Clinical study of nonsuppurative choroiditis. A report of acute diffuse choroiditis. Acta Soc Ophthalmol Jpn. 1926;30:356.Google Scholar
  9. 9.
    Ohno S, Ohguchi M, Hirose S, et al. Close association of HLA-Bw51 with Behcet’s disease. Arch Ophthalmol. 1982;100:1455–8.CrossRefGoogle Scholar
  10. 10.
    Goda C, Kotake S, Ichiishi A, Namba K, Kitaichi N, Ohno S. Clinical features in tubulointerstitial nephritis and uveitis (TINU) syndrome. Am J Ophthalmol. 2005;140:637–41.CrossRefGoogle Scholar
  11. 11.
    Umazume A, Kezuka T, Okunuki Y, Ooshita M, Usui Y, Hirano M, et al. Prediction of severe cardiac involvement by fundus lesion in sarcoidosis. Jpn J Ophthalmol. 2014;58:81–5.CrossRefGoogle Scholar
  12. 12.
    Saga U, Ozawa H, Soshi S, Nagahara K, Akeo K, Kimura C, et al. Acute retinal necrosis (Kirisawa’s uveitis). Jpn J Ophthalmol. 1983;27:353–61.Google Scholar
  13. 13.
    Ohguro N, Sonoda KH, Takeuchi M, Matsumura M, Mochizuki M. The 2009 prospective multi-center epidemiologic survey of uveitis in Japan. Jpn J Ophthalmol. 2012;56:432–5.CrossRefGoogle Scholar
  14. 14.
    McCannel CA, Holland GN, Helm CJ, Cornell PJ, Winston JY, Rimmer TG, et al. Causes of Uveitis in the General Practice of Ophthalmology. Am J Ophthalmol. 1996;121:35–46.CrossRefGoogle Scholar
  15. 15.
    Rosenbaum JT. Uveitis. An internist’s view. Arch Intern Med. 1989;149:1173–6.CrossRefGoogle Scholar
  16. 16.
    Rosenbaum JT, Wernick R. The utility of routine screening of patients with uveitis for systemic lupus erythematosus or tuberculosis. A Bayesian analysis. Arch Ophthalmol. 1990;108:1291–3.CrossRefGoogle Scholar
  17. 17.
    Han YS, Rivera-Grana E, Salek S, Rosenbaum JT. Distinguishing Uveitis Secondary to Sarcoidosis From Idiopathic Disease: Cardiac Implications. JAMA Ophthalmol. 2018;136:109–15.CrossRefGoogle Scholar
  18. 18.
    Tessler HH, Jennings T. High-dose short-term chlorambucil for intractable sympathetic ophthalmia and Behcet’s disease. Br J Ophthalmol. 1990;74:353–7.CrossRefGoogle Scholar
  19. 19.
    Ocular Behcet’s Disease Research Group Of J, Okada AA, Goto H, Ohno S, Mochizuki M. Multicenter study of infliximab for refractory uveoretinitis in Behcet disease. Arch Ophthalmol. 2012;130:592–8.CrossRefGoogle Scholar
  20. 20.
    Hooper PL, Kaplan HJ. Triple agent immunosuppression in serpiginous choroiditis. Ophthalmology. 1991;98:944–51.CrossRefGoogle Scholar
  21. 21.
    Schallhorn JM, Niemeyer KM, Browne EN, Chhetri P, Acharya NR. Difluprednate for the treatment of uveitic cystoid macular edema. Am J Ophthalmol. 2018;191:14–22.CrossRefGoogle Scholar
  22. 22.
    Jaffe GJ, Dick AD, Brezin AP, Nguyen QD, Thorne JE, Kestelyn P, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375:932–43.CrossRefGoogle Scholar
  23. 23.
    Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388:1183–92.CrossRefGoogle Scholar
  24. 24.
    Ramanan AV, Dick AD, Jones AP, McKay A, Williamson PR, Compeyrot-Lacassagne S, et al. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med. 2017;376:1637–46.CrossRefGoogle Scholar
  25. 25.
    Writing Committee for the Multicenter Uveitis Steroid Treatment T, Follow-up Study Research G, Kempen JH, Altaweel MM, Holbrook JT, Sugar EA, et al. Association between long-lasting intravitreous fluocinolone acetonide implant vs systemic anti-inflammatory therapy and visual acuity at 7 years among patients with intermediate, posterior, or panuveitis. JAMA. 2017;317:1993–2005.CrossRefGoogle Scholar
  26. 26.
    Dick AD, Rosenbaum JT, Al Dhibi HA, Belfort R Jr, Brezin A, Chee SP, et al. Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: Fundamentals Of Care for UveitiS (FOCUS) initiative. Ophthalmology. 2018;125(5):757–73.CrossRefGoogle Scholar
  27. 27.
    Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121(785–96):e3.Google Scholar
  28. 28.
    Deuter CM, Zierhut M, Mohle A, Vonthein R, Stobiger N, Kotter I. Long-term remission after cessation of interferon-alpha treatment in patients with severe uveitis due to Behcet’s disease. Arthritis Rheum. 2010;62:2796–805.CrossRefGoogle Scholar
  29. 29.
    Furie R, Khamashta M, Merrill JT, Werth VP, Kalunian K, Brohawn P, et al. Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 2017;69:376–86.CrossRefGoogle Scholar
  30. 30.
    Esterberg E, Acharya NR. Corticosteroid-sparing therapy: practice patterns among uveitis specialists. J Ophthal Inflamm Infect. 2012;2:21–8.CrossRefGoogle Scholar
  31. 31.
    Gangaputra S, Newcomb CW, Liesegang TL, Kacmaz RO, Jabs DA, Levy-Clarke GA, et al. Methotrexate for ocular inflammatory diseases. Ophthalmology. 2009;116(2188–98):e1.Google Scholar
  32. 32.
    Daniel E, Thorne JE, Newcomb CW, Pujari SS, Kacmaz RO, Levy-Clarke GA, et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol. 2010;149(423–32):e1–2.Google Scholar
  33. 33.
    Pasadhika S, Kempen JH, Newcomb CW, Liesegang TL, Pujari SS, Rosenbaum JT, et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol. 2009;148(500–9):e2.Google Scholar
  34. 34.
    Suhler EB, Thorne JE, Mittal M, Betts KA, Tari S, Camez A, et al. Corticosteroid-related adverse events systematically increase with corticosteroid dose in noninfectious intermediate, posterior, or panuveitis: post hoc analyses from the VISUAL-1 and VISUAL-2 Trials. Ophthalmology. 2017;124:1799–807.CrossRefGoogle Scholar
  35. 35.
    Nguyen QD, Hatef E, Kayen B, Macahilig CP, Ibrahim M, Wang J, et al. A cross-sectional study of the current treatment patterns in noninfectious uveitis among specialists in the United States. Ophthalmology. 2011;118:184–90.CrossRefGoogle Scholar
  36. 36.
    Dick AD, Tugal-Tutkun I, Foster S, Zierhut M, Melissa Liew SH, Bezlyak V, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013;120:777–87.CrossRefGoogle Scholar
  37. 37.
    Letko E, Yeh S, Foster CS, Pleyer U, Brigell M, Grosskreutz CL, et al. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. Ophthalmology. 2015;122:939–48.CrossRefGoogle Scholar
  38. 38.
    Mesquida M, Molins B, Llorenc V, Hernandez MV, Espinosa G, Maza M, et al. Twenty-Four month follow-up of tocilizumab therapy for refractory uveitis-related macular edema. Retina. 2018;38:1361–70.CrossRefGoogle Scholar
  39. 39.
    Fischer JA, Hueber AJ, Wilson S, Galm M, Baum W, Kitson C, et al. Combined inhibition of tumor necrosis factor alpha and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody. Arthritis Rheumatol. 2015;67:51–62.CrossRefGoogle Scholar
  40. 40.
    Lasave AF, Schlaen A, Zeballos DG, Diaz-Llopis M, Couto C, El-Haig WM, et al (2017) Twenty-four months follow-up of intravitreal bevacizumab injection versus intravitreal triamcinolone acetonide injection for the management of persistent non-infectious uveitic cystoid macular edema. Ocul Immunol Inflamm 1–9.Google Scholar
  41. 41.
    Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370:2377–86.CrossRefGoogle Scholar
  42. 42.
    Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377:1537–50.CrossRefGoogle Scholar
  43. 43.
    Olivera P, Danese S, Peyrin-Biroulet L. JAK inhibition in inflammatory bowel disease. Expert Rev Clin Immunol. 2017;13:693–703.CrossRefGoogle Scholar
  44. 44.
    Nguyen QD, Merrill PT, Clark WL, Banker AS, Fardeau C, Franco P, et al. Intravitreal sirolimus for noninfectious uveitis: a phase III sirolimus study assessing double-masKed uveitis TReAtment (SAKURA). Ophthalmology. 2016;123:2413–23.CrossRefGoogle Scholar
  45. 45.
    DiCarlo JE, Mahajan VB, Tsang SH. Gene therapy and genome surgery in the retina. J Clin Invest. 2018;128:2177–88.CrossRefGoogle Scholar
  46. 46.
    Martin-Varillas JL, Calvo-Rio V, Beltran E, Sanchez-Burson J, Mesquida M, Adan A, et al. Successful optimization of Adalimumab therapy in refractory uveitis due to Behcet’s disease. Ophthalmology. 2018;125(9):1444–51.CrossRefGoogle Scholar

Copyright information

© Japanese Ophthalmological Society 2018

Authors and Affiliations

  1. 1.Casey Eye InstituteOregon Health and Sciences UniversityPortlandUSA
  2. 2.Legacy Devers Eye InstitutePortlandUSA

Personalised recommendations